Health costs of the UK-US trade deal on pharmaceuticals

Key Points

• This analysis investigates the financial implications of the UK-US trade deal on the NHS and its effects on public health.
• Estimated costs of new pharmaceuticals under the UK-US trade deal
• Analyzed potential impacts on NHS funding and public health outcomes
• The trade deal could divert billions in NHS funding to higher drug prices, leading to adverse health outcomes.
• This diversion is projected to result in thousands of excess deaths due to reduced public health resources.